{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:36:53Z","timestamp":1789011413975,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T00:00:00Z","timestamp":1488240000000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:p>Immunoglobulin (Ig) heavy\/light chain (<jats:styled-content style=\"fixed-case\">HLC<\/jats:styled-content>) assays enable the separate quantification of the different light chain types of each Ig class. We retrospectively analyzed the correlation of heavy\/light chain ratio (<jats:styled-content style=\"fixed-case\">HLCR<\/jats:styled-content>) with clinical status and its impact on outcome in 120 patients with multiple myeloma (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>). Abnormal <jats:styled-content style=\"fixed-case\">HLCR<\/jats:styled-content> was seen more frequently in patients with poorer myeloma response, and it appeared to be more sensitive for detecting clonality in IgA myeloma compared to IgG myeloma after treatment. Among the 85 patients who achieved \u2265<jats:styled-content style=\"fixed-case\">VGPR<\/jats:styled-content>, the patients remained <jats:styled-content style=\"fixed-case\">HLCR<\/jats:styled-content> abnormal were showed significantly shorter overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) compared to those achieving a normal <jats:styled-content style=\"fixed-case\">HLCR<\/jats:styled-content> (not reached <jats:italic>vs<\/jats:italic> 55.5\u00a0months, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.032). This correlation was seen in IgA myeloma patients (not reached <jats:italic>vs<\/jats:italic> 30.1\u00a0months, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.014), but not in IgG myeloma patients when patients were analyzed separately. Univariate and multivariate analysis of factors that may affect survival identified abnormal <jats:styled-content style=\"fixed-case\">HLCR<\/jats:styled-content> at the best response as the only independent risk factor (hazard ratio, 4.7; 95% confidence interval, 1.4\u00a0\u2013\u00a015.26; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.012) for shorter <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> in this subset of patients. This study highlighted the <jats:styled-content style=\"fixed-case\">HLC<\/jats:styled-content> assay as a prognostic predictor in patients with IgA myeloma.<\/jats:p>","DOI":"10.1111\/cas.13125","type":"journal-article","created":{"date-parts":[[2016,11,27]],"date-time":"2016-11-27T08:46:38Z","timestamp":1480236398000},"page":"187-192","source":"Crossref","is-referenced-by-count":10,"title":["Abnormal heavy\/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma"],"prefix":"10.1111","volume":"108","author":[{"given":"Yasuhito","family":"Suehara","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology Department of Internal Medicine Kameda Medical Center Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takamatsu","sequence":"additional","affiliation":[{"name":"Cellular Transplantation Biology Kanazawa University Graduate School of Medical Science Kanazawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Department of Internal Medicine Kameda Medical Center Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Department of Internal Medicine Kameda Medical Center Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Narita","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Department of Internal Medicine Kameda Medical Center Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Usui","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Department of Internal Medicine Kameda Medical Center Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Department of Internal Medicine Kameda Medical Center Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Endean","sequence":"additional","affiliation":[{"name":"The Binding Site Ltd. Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Matsue","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Department of Internal Medicine Kameda Medical Center Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2009.123828"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.189"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12679"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.197"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2014.231985"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12050"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.118"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.247"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/096382800296575"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.293"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1373\/49.4.676"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24268"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14026"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.13125","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.13125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T01:39:58Z","timestamp":1696297198000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.13125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1111\/cas.13125"],"URL":"https:\/\/doi.org\/10.1111\/cas.13125","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}